MagVenture announced FDA clearance for accelerated TMS (aTMS) protocols to treat major depressive disorder in adults. The clearance lets clinicians deliver from two up to ten sessions per day over a condensed schedule, allowing a full course to be completed in days rather than the traditional four to six weeks,.
The clearance applies to MagVenture's TMS Therapy system and covers both repetitive TMS (rTMS) and intermittent theta-burst stimulation (iTBS) protocols, with or without MRI-based neuronavigation, and, per the company, required no hardware, stimulation-output, waveform, or safety changes. Standard scalp-based targeting remains clinically appropriate for routine care.
Andre R. Brunoni of UT Southwestern Medical Center noted the flexibility lets clinicians tailor protocols to the individual patient rather than a fixed schedule. MagVenture, which operates in more than 60 countries with 35 years of experience, positioned the clearance as a way to compress the timeline for patients who cannot commit to weeks of daily visits.
For clinics, accelerated protocols mean higher throughput and the ability to serve patients who travel from a distance for treatment.
Source
Reporting based on coverage from MagVenture. This article is editorial summary intended for general information; it is not medical advice.
